Is clindamycin safe to use during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clindamycin Safety in Pregnancy

Clindamycin is generally safe for use during pregnancy as it is classified as FDA Pregnancy Category B, indicating no evidence of fetal risk in animal studies and no adequate studies showing risk in pregnant women. 1

Safety Profile

Clindamycin has been well-studied in pregnancy with the following key findings:

  • The FDA classifies clindamycin as Pregnancy Category B, indicating relative safety during pregnancy 1
  • Systemic administration of clindamycin during second and third trimesters has not been associated with increased frequency of congenital abnormalities 2
  • Animal reproduction studies using oral doses up to 600 mg/kg/day revealed no evidence of teratogenicity 2
  • Clindamycin is considered among the antibiotics generally regarded as safe and effective in pregnancy 3

Clinical Guidelines for Use in Pregnancy

Recent guidelines specifically support clindamycin use in pregnant patients:

  • For bacterial vaginosis treatment during pregnancy, oral clindamycin 300mg twice daily for 7 days is recommended as an effective treatment option 4
  • For hidradenitis suppurativa in pregnancy requiring systemic antibiotics, guidelines suggest that "oral clindamycin can be used as there is evidence it is safe for use in pregnancy" (Conditional recommendation, Moderate quality evidence) 1
  • Oral rifampin and clindamycin combination can be used in select pregnant patients with severe hidradenitis suppurativa 1

Route of Administration Considerations

The safety profile differs slightly based on administration route:

Oral Administration

  • Oral clindamycin has been studied extensively in pregnancy with no increased risk of congenital abnormalities 2
  • Should be used during first trimester only if clearly needed 2

Topical Administration

  • Topical clindamycin for acne treatment is also classified as Pregnancy Category B 1
  • Systemic absorption from topical application is minimal, further reducing potential fetal exposure

Potential Concerns and Monitoring

While generally safe, certain precautions should be observed:

  • Monitor for gastrointestinal side effects, which are the most common adverse reactions
  • Clindamycin has potential to cause adverse effects on the breastfed infant's gastrointestinal flora if used while nursing 2
  • Monitor breastfed infants for possible adverse effects such as diarrhea, candidiasis, or rarely blood in stool indicating possible antibiotic-associated colitis 2

Clinical Efficacy in Pregnancy-Specific Conditions

For bacterial vaginosis in pregnancy:

  • A 3-day course of clindamycin vaginal cream was significantly more efficacious than placebo in treating bacterial vaginosis during the second trimester 5
  • However, some studies show mixed results regarding prevention of preterm birth with clindamycin treatment for bacterial vaginosis 6, 7

Conclusion

Clindamycin can be safely used during pregnancy when clinically indicated, with the benefit of treating infection typically outweighing potential risks. The medication has a well-established safety profile in pregnancy with no evidence of increased risk of congenital abnormalities.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A Review of Antibiotic Use in Pregnancy.

Pharmacotherapy, 2015

Guideline

Bacterial Vaginosis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis.

BJOG : an international journal of obstetrics and gynaecology, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.